These findings collectively demonstrate that impaired NET formation, whether due to PAD4 deficiency or HCQ treatment, resulted in reduced ROS production within the tumor microenvironment, while DNase-mediated NET degradation did not impact ROS levels. This evidence concerns the gene PADI4 and neoplasm.